CABR

Caring Brands, Inc. (CABR) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Caring Brands, Inc. is a Nevada corporation operating as a wellness consumer products company, focusing on over-the-counter (OTC) and prescription-grade health products. The company is classified as a smaller reporting company and an emerging growth company. As of May 11, 2026, there were 9,091,506 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero from $1,469 in the prior year quarter as the company continues to develop and commercialize products without meaningful sales.
• Increased Operating Loss: Operating loss increased by approximately 219% to $1.72 million, driven primarily by a 200% increase in payroll expenses ($1.1M vs $367k) and a 683% increase in professional service fees ($532k vs $68k) related to capital markets activities and public company compliance.
• Debt Conversion: The company converted a $200,000 convertible promissory note into 299,581 shares of common stock, eliminating long-term debt but incurring significant non-cash interest expense ($286,989).
• Capital Structure Changes: The company issued Series A Convertible Redeemable Preferred Stock (Mezzanine Equity) valued at $3.79 million. Concurrently, it repurchased and retired 6.25 million shares of common stock from related parties for $3.075 million.
• Accretion Impact: A non-cash accretion charge of $1.84 million was recorded to adjust the Series A Preferred Stock to its redemption value, significantly increasing the net loss attributable to common stockholders.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Going Concern: Management believes existing cash resources ($2.03M) are sufficient to fund operations for at least the next twelve months. However, the company has an accumulated deficit of $9.15 million and continues to incur losses, creating a going concern uncertainty.
• Listing Compliance Risk: On April 7, 2026, the company received a Nasdaq Staff Delisting Determination letter for failing to meet the $2.5 million stockholders' equity requirement. The company is working to regain compliance.
• Internal Control Deficiencies: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses including the failure to identify multiple journal entries and a lack of formal controls for related party transactions.
• Settlements and Contingencies: The company settled disputes with NovoDX Corporation (related party) and D. Boral Capital, agreeing to repurchase shares and issue new shares/cash to resolve claims regarding lock-up violations and license agreements.
• Impairment History: While no impairment was recorded in Q1 2026, the company fully impaired its intellectual property license and investment in NovoDX in late 2025, resulting in zero carrying value for these assets.

Investor Verification Checklist

• Nasdaq Compliance Status: Verify the company's progress in regaining compliance with Nasdaq listing standards following the April 2026 delisting notice.
• Series A Redemption Risk: Review the terms of the Series A Preferred Stock, specifically the "Triggering Events" that could force the company to redeem the shares for approximately $3.6 million in cash.
• Related Party Transactions: Scrutinize the repurchase of 6.25 million shares from related parties (including NovoDX and executives) and the valuation used, as these transactions significantly altered the capital structure.
• Revenue Generation Timeline: Assess the company's product pipeline and commercialization strategy, given the lack of revenue for two consecutive quarters.
• Internal Control Remediation: Monitor the company's efforts to remediate the identified material weaknesses in internal controls over financial reporting.